+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A novel Sin Nombre virus DNA vaccine and its inclusion in a candidate pan-hantavirus vaccine against hantavirus pulmonary syndrome (HPS) and hemorrhagic fever with renal syndrome (HFRS)



A novel Sin Nombre virus DNA vaccine and its inclusion in a candidate pan-hantavirus vaccine against hantavirus pulmonary syndrome (HPS) and hemorrhagic fever with renal syndrome (HFRS)



Vaccine 31(40): 4314-4321



Sin Nombre virus (SNV; family Bunyaviridae, genus Hantavirus) causes a hemorrhagic fever known as hantavirus pulmonary syndrome (HPS) in North America. There have been approximately 200 fatal cases of HPS in the United States since 1993, predominantly in healthy working-age males (case fatality rate 35%). There are no FDA-approved vaccines or drugs to prevent or treat HPS. Previously, we reported that hantavirus vaccines based on the full-length M gene segment of Andes virus (ANDV) for HPS in South America, and Hantaan virus (HTNV) and Puumala virus (PUUV) for hemorrhagic fever with renal syndrome (HFRS) in Eurasia, all elicited high-titer neutralizing antibodies in animal models. HFRS is more prevalent than HPS (>20,000 cases per year) but less pathogenic (case fatality rate 1-15%). Here, we report the construction and testing of a SNV full-length M gene-based DNA vaccine to prevent HPS. Rabbits vaccinated with the SNV DNA vaccine by muscle electroporation (mEP) developed high titers of neutralizing antibodies. Furthermore, hamsters vaccinated three times with the SNV DNA vaccine using a gene gun were completely protected against SNV infection. This is the first vaccine of any kind that specifically elicits high-titer neutralizing antibodies against SNV. To test the possibility of producing a pan-hantavirus vaccine, rabbits were vaccinated by mEP with an HPS mix (ANDV and SNV plasmids), or HFRS mix (HTNV and PUUV plasmids), or HPS/HFRS mix (all four plasmids). The HPS mix and HFRS mix elicited neutralizing antibodies predominantly against ANDV/SNV and HTNV/PUUV, respectively. Furthermore, the HPS/HFRS mix elicited neutralizing antibodies against all four viruses. These findings demonstrate a pan-hantavirus vaccine using a mixed-plasmid DNA vaccine approach is feasible and warrants further development.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 036989810

Download citation: RISBibTeXText

PMID: 23892100

DOI: 10.1016/j.vaccine.2013.07.025


Related references

Application of a recombinant baculovirus expressing hantavirus nucleocapsid protein as a diagnostic antigen in IFA test: cross reactivities among 3 serotypes of hantavirus which causes hemorrhagic fever with renal syndrome (HFRS). Journal of Veterinary Medical Science 55(6): 1047-1050, 1993

Application of a Recombinant Baculovirus Expressing Hantavirus Nucleocapsid Protein as a Diagnostic Antigen in Ifa Test: Cross Reactivities among 3 Serotypes of Hantavirus which Causes Hemorrhagic Fever with Renal Syndrome(Hfrs). The Journal of Veterinary Medical Science 55(6): 1047-1050, 1993

Spectrum of hantavirus infection: hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome. Annual Review of Medicine 50: 531-545, 1999

Protective Effectiveness of Inactivated Hantavirus Vaccine Against Hemorrhagic Fever With Renal Syndrome. Journal of Infectious Diseases 217(9): 1417-1420, 2018

Effectiveness of inactivated hantavirus vaccine on the disease severity of hemorrhagic fever with renal syndrome. Kidney Research and Clinical Practice 37(4): 366-372, 2019

A Nonfatal Case of Dobrava Hantavirus Hemorrhagic Fever with Renal Syndrome Combined with Hantavirus Cardiopulmonary Syndrome. Journal of Global Infectious Diseases 10(1): 22-25, 2018

Development of inactivated vaccine of hemorrhagic fever with renal syndrome (HFRS) virus. International Journal of Immunopharmacology 10(Supp-S1): 73-0, 1988

Serological analysis of hemorrhagic fever with renal syndrome (HFRS) patients in Far Eastern Russia and identification of the causative hantavirus genotype. Archives of Virology 148(8): 1543-1556, 2003

Immunopathogenesis of hantavirus pulmonary syndrome and hemorrhagic fever with renal syndrome: Do CD8+ T cells trigger capillary leakage in viral hemorrhagic fevers?. Immunology Letters 113(2): 117-120, 2007

Hemorrhagic fever with renal syndrome and coexisting hantavirus pulmonary syndrome. Kidney Research and Clinical Practice 31(2): 118-120, 2012

Immunopathogenesis of hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome. Acta Medica Croatica 57(5): 407-414, 2004

The Fifth International Conference on Hemorrhagic Fever with Renal Syndrome, Hantavirus Pulmonary Syndrome, and Hantaviruses. Emerging Infectious Diseases 8(1): 109, 2002

Preparation of recombinant nucleocapsid protein of Hantavirus as the antigen for colloidal gold immuno-chromatographic assay to detect antibodies in hemorrhagic fever with renal syndrome(HFRS). Zhonghua Weishengwuxue He Mianyixue Zazhi 27(2): 192-196, 2007

Hemorrhagic Fever with Renal Syndrome in the New, and Hantavirus Pulmonary Syndrome in the Old World: paradi(se)gm lost or regained?. Virus Research 187: 55-58, 2015

Serum Cytokine Profiles Differentiating Hemorrhagic Fever with Renal Syndrome and Hantavirus Pulmonary Syndrome. Frontiers in Immunology 8: 567, 2017